Latest news for Cookpad (OTC:CKPDY) Stock

Cookpad Inc is a Japanese Internet company that specializes in the sharing of user-created food recipes. The company operates Cookpad, Japan's largest recipe-sharing site, which allows users to upload and browse recipes. While the Cookpad site is the company's largest segment, it also offers various services to its online users, such as professional recipes, discussion boards, cooking lessons, weight-loss advice, and home food-delivery services. In 2014, the company expanded outside of Japan, where it still generates the majority of its revenue. Cookpad now also operates in Indonesia, the Philippines, South America, the United States, and the United Kingdom.

Cookpad Inc

News

CTRM

Castor Maritime Announces Agreement To Acquire 2015-Built Ultramax Dry Bulk Carrier For $25.5M Through Wholly-Owned Subsidiary

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $83 to $88.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.78, a high estimate of $400.00, and a low estimate of $240.00. Observing a 13.18% increase, the current average has risen from the previous average price target of $297.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1721912420_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of United Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$321.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of United Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>About United Therapeutics</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>United Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: United Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 33.7%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 45.24%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.42% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.49% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: United Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UTHR

Navigating 9 Analyst Ratings For United Therapeutics

Wedbush analyst David Chiaverini maintains Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) with a Neutral and raises the price target from $23 to $25.

PPBI

Wedbush Maintains Neutral on Pacific Premier Bancorp, Raises Price Target to $25

In his speech at the Republican National Convention on Wednesday, Vice Presidential nominee J.D. Vance explained America&#8217;s housing affordability crisis and contrasted it with <a href="https://www.benzinga.com/real-estate/24/07/39634709/housing-market-stuck-until-2026-economists-reveal-surprising-reasons">what economists and policy experts say</a>.
The Ohio senator and former venture capitalist Vance offered a vision of a housing market battered by Wall Street malfeasance, stagnant wages, and illegal immigration. &#8220;Wall Street barons crashed the economy and American builders went out of business,&#8221; Vance said during his speech. &#8220;As tradesmen scrambled for jobs, houses stopped being built.&#8221;
Don't Miss:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
&#8220;And then the Democrats flooded this country with millions of illegal aliens,&#8221; he continued. &#8220;So citizens had to compete with people who shouldn&#8217;t even be here for precious housing.&#8221;
In June, he tweeted, &#8220;Not having 20 million illegal aliens who need to be housed (often at public expense) will make housing more affordable for American citizens.&#8221; That is not the problem, the data suggests. According to the National Review, roughly 223 million Americans own or live in homes that are owned, compared to about three million illegal immigrants who are thought to reside in owner-occupied homes. More than that, mass deportation, as suggested by Vance, could even exacerbate the housing affordability problem. Immigrants make up a sizable portion of the construction workforce, and their removal could further slow housing production. According to a report issued in 2021 by the National Association of Home Builders, immigrants account for about 24% of workers in the construction industry.
See Also: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
Economists and housing experts argue that the problem goes back to the 2008 financial crash, which led to a drop in new home construction. Then, restrictive zoning laws, the COVID-19 pandemic, increased construction costs, and changing demographics drove up housing prices. According to the Government Accountability Office, the current shortage of affordable housing in the U.S. is the product of high interest rates, low inventory, and the growing number of adults looking for homes. More than that, during the pandemic, record-low interest rates and a shift toward remote work fueled demand, particularly for larger homes. The combination of limited supply and increased demand drove prices to historic highs in many markets.&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
&#8220;The simple fact is there are not enough homes in this country, and that&#8217;s pushing homeownership out of reach for too many families,&#8221; Orphe Divounguy, senior economist at Zillow, said in June. &#8220;Filling the housing shortage is the long-term answer to making housing more affordable. We are in a big hole, and it will take more than the status quo to dig ourselves out of it." According to Zillow, despite recent efforts to ramp up construction, the housing shortage is worsening. The deficit <a href="https://www.benzinga.com/real-estate/24/06/39417022/zillow-economist-admits-we-are-in-a-big-hole-as-u-s-housing-shortage-hits-4-5-million-despite-constr">grew to 4.5 million homes in 2022</a>, up from 4.3 million the previous year.
While the pandemic sparked a surge in homebuilding, with 2022 marking the strongest year for construction since the early days of the Great Recession, the uptick in building activity has been insufficient to meet the growing demand. While 1.4 million new homes were built in 2022, U.S. households increased by 1.8 million during the same period.&nbsp;
As demand continues to outpace supply, prices remain elevated, putting homeownership increasingly out of reach for many Americans – which is not what Vance suggested during his speech. 
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>Can you guess which type of investments Morgan Stanley says will reach $2.7 trillion by 2027?<a href="https://www.benzinga.com/money/percent"> It even offers up to 20% APY potential to accredited investors up to $300 back in bonus for new users.</a></li>
</ul>

Real Estate

Here's What Republican VP Nominee JD Vance Has Said About The Housing Market – You Might Be Shocked

INDOCHINO, the global leader in custom apparel, and Nordstrom, the renowned fashion retailer, are pleased to announce the expansion of their successful partnership with the addition of five new INDOCHINO shop-in-shop locations across the United States.
Building upon the phenomenal success of this collaboration since 2020, INDOCHINO will now offer its made to measure suiting experience in the following Nordstrom locations:
<ul>
<li>Nordstrom Los Cerritos Center - Cerritos, CA</li>
<li>Nordstrom Alderwood Mall - Lynnwood, WA</li>
<li>Nordstrom Thousand Oaks - Thousand Oaks, CA</li>
<li>Nordstrom Irvine Spectrum Center - Irvine, CA</li>
<li>Nordstrom Fashion Centre at Pentagon City - Pentagon City, VA</li>
</ul>

Nordstrom Strengthens Partnership With INDOCHINO, With The Addition Of 5 New Shop-In-Shop Locations Across The US

4 analysts have shared their evaluations of Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.0, a high estimate of $40.00, and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 11.11% from the previous average price target of $31.50.
<img src="https://www.benzinga.com/files/images/story/2024/1721912409_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Flex. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$39.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Flex. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Flex compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Flex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Flex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FLEX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Flex analyst ratings.</a>
<h2>Delving into Flex's Background</h2>
Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.
<h3>Unraveling the Financial Story of Flex</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Challenges: Flex's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -20.02%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Flex's net margin is impressive, surpassing industry averages. With a net margin of 8.77%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Flex's ROA stands out, surpassing industry averages. With an impressive ROA of 2.05%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Flex's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.7, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLEX

The Latest Analyst Ratings For Flex

Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is hitting the brakes on its latest innovation, <a href="https://www.benzinga.com/quote/LULU/news">the Breezethrough collection</a>. 
JPMorgan analyst Matthew R. Boss has slashed his 2024 earnings estimates and removed the stock from his Analyst Focus List. The company&#8217;s stock, currently priced at $272.06, faces a revised price target of $338.00 for December 2025, down from a previous $457.00.
Lululemon has pulled its Breezethrough collection from both online and in-store sales just weeks after its launch. The Breezethrough collection, aimed at hot, low-impact workouts, faced criticism over its design, with a 3.1-star rating from 112 reviews highlighting issues like unflattering seams and discomfort.
<h2 class="wp-block-heading">Lululemon&#8217;s Innovation &#8216;Pause&#8217; Raises Concerns</h2>
Lululemon's Breezethrough collection, launched on July 9, is experiencing significant pushback.
According to Boss's fieldwork, "LULU has now paused sales on the recently launched Breezethrough collection" after receiving "guest feedback" that highlighted design flaws. 
The collection, intended for hot, low-impact workouts, has been criticized for its "V" shaped back seam and "U" shaped front seam, which customers found unflattering.
Also Read: <a href="https://www.benzinga.com//node/39939705">What&#8217;s Going On With Lululemon Stock?</a>
<h2 class="wp-block-heading">&#8216;Execution Concerns&#8217;</h2>
The Breezethrough line was expected to drive growth in Lululemon's women's leggings category through the second half of 2024. 
However, the pause in sales "compounds recent in-stock/color palette &#8216;execution&#8217; concerns," Boss notes. 
The innovation was a key driver behind the company's revenue growth expectations for the latter part of the year. As a result, JPMorgan has lowered its 2H24 revenue growth estimate to 8%, below the street's forecast of 13%.
<h2 class="wp-block-heading">Op Margins Expected To Drop</h2>
The halted innovation has led to a revision in earnings projections. Boss now models a decrease in 2H24 U.S. revenue growth to flat year-over-year, with international growth expected to moderate. This adjustment contributes to a lowered full-year EPS forecast of $13.90, versus the street's $14.34. 
The firm&#8217;s operating margins are anticipated to drop to 22.8%, reflecting a fixed cost deleverage.
While Lululemon's stock has seen strong performance, current challenges with product innovation and execution issues are weighing on its growth prospects. Investors should brace for volatility as the company adjusts its strategies.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/39769497">Lululemon Accused Of Misleading Sustainability Claims In New Lawsuit: Report</a></li>
</ul>
Photo: Shutterstock

Analyst Color

LULU

Lululemon Hits Brakes On New Collection: JPMorgan Lowers Estimates After Innovation Setback

Canaccord Genuity analyst Joseph Vafi maintains ASGN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) with a Buy and maintains $115 price target.

ASGN

Canaccord Genuity Maintains Buy on ASGN, Maintains $115 Price Target

Wedbush analyst David Chiaverini maintains CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) with a Neutral and raises the price target from $18 to $21.

CVBF

Wedbush Maintains Neutral on CVB Financial, Raises Price Target to $21

Instructure shareholders to receive $23.60 per share in cash; Instructure to become a privately held company upon completion of the transaction
SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Instructure Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INST#NYSE">INST</a>) ("Instructure"), a leading learning ecosystem, today announced that it has entered into a definitive agreement to be acquired by investment funds managed by KKR, a leading global investment firm, for $23.60 per share in an all-cash transaction valued at an enterprise value of approximately $4.8 billion. The per-share purchase price represents a premium of 16 percent over Instructure's unaffected share price of $20.27 as of May 17, 2024, the last trading day prior to media reports regarding a potential transaction.&nbsp; KKR, with participation from Dragoneer Investment Group, will acquire all outstanding shares, including those shares owned by Instructure's existing majority owner, Thoma Bravo, a leading software investment firm, which took the company public in 2021.

INST

Instructure To Be Acquired By KKR For $4.8B, Or $23.60 Per Share In An All-Cash Transaction

EZFL

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

SNES

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Capitol Federal Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFN#NASDAQ">CFFN</a>) with a Market Perform and raises the price target from $6 to $6.5.

CFFN

Keefe, Bruyette & Woods Maintains Market Perform on Capitol Federal Finl, Raises Price Target to $6.5

Earnings

American Airlines CFO Expects FY Operating Margin Between 3.5% And 5.5%

American Airlines CFO Announces Revised Delivery Of 20 New Mainline Aircraft This Year, Down From 22; Expects To Achieve Approximately $400M In Cost Savings In 2024

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Capital City Bank Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCBG#NASDAQ">CCBG</a>) with a Outperform and raises the price target from $37 to $38.

CCBG

Keefe, Bruyette & Woods Maintains Outperform on Capital City Bank Group, Raises Price Target to $38

Barclays analyst Tavy Rosner maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Overweight and lowers the price target from $320 to $286.

NICE

Barclays Maintains Overweight on NICE, Lowers Price Target to $286

Guidance

RELX

RELX Says "We Continue To See Positive Momentum Across The Group, And We Expect Another Year Of Strong Underlying Growth In Revenue And Adjusted Operating Profit, As Well As Strong Growth In Adjusted EPS On A Constant Currency Basis"

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has yet again provided a fresh timeline for the &#8220;Actually Smart Summon&#8221; feature on its cars with full self-driving (FSD) driver assistance technology deployed.
What Happened: The code for the &#8220;Actually Smart Summon&#8221; feature is different and it will be bundled with future versions of Tesla&#8217;s FSD, Musk said in a post on X, formerly Twitter.
&#8220;Technically A&#x2A;&#x2A; is separate code, but it will be bundled with 12.5.x next month.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yes. Technically ASS is separate code, but it will be bundled with 12.5.x next month.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1816282993465479327?ref_src=twsrc%5Etfw">July 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Actually Smart Summon will allow users to summon their Tesla cars and banish them once they are done using it with the Tesla app. Musk has previously provided different timelines for the feature being deployed but they have been delayed time and again. 
&#8220;(Actually) Smart Summon is almost done,&#8221; Musk said as long back as October 2022.
Earlier this year, he again said that the feature would be &#8220;coming soon,&#8221; but without providing a clearer timeline. 
Why It Matters: Tesla started rolling out <a href="https://www.benzinga.com/news/24/07/39900392/teslas-fsd-version-12-5-doesnt-support-sunglasses-yet-contrary-to-elon-musks-word">version 12.5 of FSD </a>earlier this month. The company is currently advancing the capability of the technology in a bid to achieve complete vehicle autonomy. 
During Tesla&#8217;s second-quarter earnings call earlier this week, Musk pegged vehicle autonomy to be the major driver of value for Tesla. 
&#8220;So I recommend anyone who doesn&#8217;t believe that Tesla would sell vehicle autonomy should not hold Tesla stuff. They should sell their Tesla stuff. If you believe Tesla will sell autonomy, you should buy Tesla stuff,&#8221; <a href="https://www.benzinga.com/news/24/07/39900392/teslas-fsd-version-12-5-doesnt-support-sunglasses-yet-contrary-to-elon-musks-word">Musk said.</a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39950408/elon-musk-agrees-with-former-executive-who-thinks-everyone-has-strong-opinions-on-tesla-unlike-in-th" target="_blank" rel="noreferrer noopener">Elon Musk Agrees With Former Executive Who Thinks ‘Everyone' Has ‘Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH</a></li>
</ul>
Photo courtesy: Tesla

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Cookpad

News

Latest news for Cookpad (OTC:CKPDY) Stock